Bo Sheng Ji Announces Two Latest Preclinical Research Advances Selected for AACR 2024, Involving Two Key CAR-Vδ1T Cell Products from the Company’s Internationally Leading Universal UCAR-Vδ1T Platform. The Abstracts Are Now Published on the AACR Official Website.
The American Association for Cancer Research (AACR) Annual Meeting is one of the world's oldest and largest academic conferences on cancer research. The meeting focuses on all aspects of high-quality cancer research and innovation, serving as the focal point of global cancer research, gathering the most cutting-edge research achievements in the field of oncology. This year's AACR Annual Meeting will be held at the local time.April 5-10, 2024Held in San Diego, USA.
In response to the significant challenges faced by CAR-T therapy commercialization in terms of cost and time, Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD began laying out plans for development as early as 2018.UCAR-Vδ1T Cell Product, and confirmed that Vδ1 T cells have more advantages and potential in tumor treatment, while establishing under cGMP conditionsCommercial-scaleThe unique preparation process for producing CAR-Vδ1T cells addresses the challenges of transfection and cryopreservation of CAR-Vδ1T cells.
Recently, the project "Development of Universal Cell Therapy for Malignant Tumors Based on γδT Cell R&D Platform" was successfully selected as2023 National Biomedicine Innovation Center Cell Therapy "Challenge Leader" Key Project, ranking first among key projects and 5th nationwide among all 89 awarded projects.
Allogeneic universal CAR-Vδ1T cell products are providing a new approach for the clinical treatment of hematologic malignancies and solid tumors, offering patients more accessibility and options. At this year's AACR conference, Bo Shengji Medicine Science and Technology (Suzhou) Co., LTD will disclose for the first time its developments based on the Vδ1T cell R&D platform.Excellent Preclinical In Vivo and In Vitro Research Data of CAR-Vδ1T Cell Product, The information of the poster display is as follows:
The "off-the-shelf" CD19-CAR-Vδ1T cells demonstrated an enhanced therapeutic effect on B-cell malignancy models
CD19-CAR-Vδ1T, an allogeneic off-the-shelf cell product, demonstrates potent antitumor efficacy in B-cell lineage tumor models.
Immunology - Adoptive Cell Therapy
Tuesday, April 9, 20241:30 PM-5:00 PM (Local Time)
April 10, 2024 (Wednesday) 4:30AM-8:00AM (Beijing Time)
CD19-CAR-Vδ1T is a fully self-developed allogeneic universal product targeting CD19 by Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD. It can specifically eliminate tumor cells in mice, achieve good and lasting amplification in vivo, without causing GVHD, ensuring its safety.
This study achieved each batch up to2×1011The preparation volume solved the problem of large-scale production while breaking through the technical difficulty of low transfection efficiency in allogeneic products, and overcoming the technical barriers of cryopreservation processes for allogeneic products.
A B7-H3-CAR-modified Vδ1 T cells showed potent anti-solid tumor potential
B7-H3-CAR-Modified Vδ1 T Cells Exhibit Excellent Anti-Solid Tumor Potential
Immunology - Adoptive Cell Therapy
Tuesday, April 9, 20241:30 PM-5:00 PM (Local Time)
April 10, 2024 (Wednesday) 4:30AM-8:00AM (Beijing Time)
B7-H3-CAR-Vδ1T is another groundbreaking universal CAR-Vδ1T cell therapy independently developed by Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD, targeting various solid tumors without the need for gene editing. Due to its CAR structure incorporating key components that significantly enhance the anti-tumor persistence of Vδ1T cells, it offers multiple anti-tumor pathways, robust tumor infiltration capabilities, superior anti-tumor persistence, and the potential to overcome solid tumors.
This study shows that: In multiple solid tumor mouse models, a single intravenous infusion of the product can completely eliminate tumors in most mice, with an average tumor clearance rate of over 80%; meanwhile, it demonstrates strong tumor infiltration and expansion capabilities in mice; it has good safety, with no toxic side effects observed.
Dr. Fengtao You, Dean of the Bo Sheng Ji New Drug Research Institute, stated：
In response to the current issues of low accessibility and significant commercialization challenges faced by autologous CAR-T cell therapies, the development of next-generation cell therapies that are effective and off-the-shelf has important clinical value and social significance. Among these, CAR-Vδ1T (CAR-modified Vδ1T) cell therapies based on Vδ1T cells hold great potential. We are very pleased that the preclinical research results of two CAR-Vδ1T cell products from Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., Ltd.'s internationally leading universal UCAR-Vδ1T platform will be presented at this year’s AACR Annual Meeting, where we will disclose for the first time the excellent preclinical in vivo and in vitro study data of our CAR-Vδ1T cell products.
Among themCD19-CAR-Vδ1T ProductNot only can it target traditional B-cell malignancies, but also, due to its natural tissue residency, it has the potential to become a product with a vast market.A Disruptor in the Field of Autoimmune Diseases.At the same time, ourB7-H3-CAR-Vδ1T Product,Its tumor homing ability makes it stand out among many immune cells, and it is expected to become a solution.The Golden Key to Solid Tumor Cell Therapy。We will continue to move forward, constantly developing more innovative biopharmaceuticals that are highly accessible, effective, and safe, enabling patients to truly benefit and bringing welfare to a wide range of patients.
Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD was registered on May 31, 2010, in Suzhou Industrial Park, Jiangsu Province. It is a national high-tech enterprise with primary development goals of CAR-T, CAR-VδT, and CAR-NK cell product research, production, and clinical transformation for tumor immunotherapy. The company focuses on developing breakthrough First-in-class and Best-in-class CAR-T cell drugs with internationally leading standards.
A nearly 10,000-square-meter commercial production base meeting GMP standards has been built, which is currently the leading fully automated CAR-T cell production base in the Asia-Pacific region. It houses world-class GMP plasmid and lentivirus production and purification workshops, P2 safety laboratories, quality control rooms, and R&D laboratories. The facility features a complete production chain system covering plasmids, lentiviruses, and all the way to CAR-T cell preparation. It has an entire industrial chain layout encompassing original innovation, quality control, commercial production, and cold chain transportation. It is one of the few enterprises in China with the most comprehensive fully automated and fully enclosed CAR-T cell production line.
